Five subcutaneous doses of insulin glargine (0, 0.5, 1.0, 1.5, and 2.0 units/kg) were investigated on separate occasions using the 24-h euglycemic clamp technique. Results — Glargine duration of ...

The Europe-wide approval is the first ever insulin treatment licensed through the European Medicines Agency's biosimilar pathway, and the fourth diabetes product approved in the EU from the Lilly ...

One group received two oral drugs (metformin plus the sulfonylurea glimepiride [Amaryl]) plus morning doses of glargine insulin (Lantus); the other group received twice-daily premixed insulin (70% ...